BioNet and Bio Farma Sign Strategic MoU to Expand TdaP Vaccine Access in ASEAN
JAKARTA, Indonesia, June 3, 2025 /PRNewswire/ -- BioNet, a Franco-Thai vaccine biotech group, and PT Bio Farma (Persero), Indonesia's state-owned vaccine manufacturer, have signed a Memorandum of Understanding (MoU) to collaborate on development and regional distribution of a combined TdaP vaccine (tetanus, diphtheria, and acellular recombinant pertussis).
Signed during the State Visit of French President Emmanuel Macron to Indonesia, the agreement underscores a commitment to accelerating access to innovative vaccines across Southeast Asia. The partnership combines BioNet's proprietary recombinant pertussis technology and global clinical experience with Bio Farma's large-scale manufacturing and public health reach to address critical immunization needs in ASEAN.
"This agreement reflects our shared goal to make next-gen vaccines accessible where needed most," said Philippe Guillot-Chêne, CEO of BioNet Europe. "By aligning our strengths, BioNet and Bio Farma strengthen the regional health ecosystem and ASEAN's capacity to respond to current and emerging infectious disease threats."
The MoU outlines cooperation in clinical development, regulatory alignment, and market access. Bio Farma leads clinical trials and regulatory submissions in Indonesia, while BioNet handles other ASEAN countries. The collaboration aims to reduce vaccine introduction from 10–15 years to less than five.
"Through this collaboration, we are reinforcing Indonesia's commitment to regional vaccine self-sufficiency and innovation," said Yuliana Indriati, Director of Business Development at Bio Farma. "With BioNet's advanced recombinant pertussis technology and our production capacity, we aim to ensure timely access to TdaP vaccines for Indonesian adolescents, pregnant women, and the elderly. We hope this product will soon be part of our immunization program."
The TdaP vaccine combines Bio Farma's Td and BioNet's aP antigens. It targets the ASEAN market with an estimated 10–15 million doses annually, valued at around USD 200 million.
This partnership aims to strengthen pandemic preparedness, build resilient vaccine supply chains, and improve equitable healthcare access across Southeast Asia.
This step aligns with President Prabowo Subianto's Asta Cita, particularly the goals of national self-reliance in economy, food, and energy, improving quality of life, and expanding access to affordable, high-quality healthcare.
About BioNet
BioNet is a French-Thai vaccine organization developing and manufacturing genetically designed vaccines with a global footprint. The group includes:
- BioNet Europe, which submitted an EU-GMP recombinant pertussis vaccine application to the EMA.
- BioNet Asia, based in Thailand, producing the world's only standalone recombinant pertussis vaccine.
BioNet has developed a clinically validated mRNA platform, enabling partnerships for technology transfer, regional manufacturing, and pandemic preparedness.
About Bio Farma
PT Bio Farma (Persero) is Indonesia's largest state-owned pharmaceutical holding company, offering integrated services from R&D and manufacturing to distribution, retail pharmacies, clinics, and labs. Its head office and manufacturing site are in Bandung, West Java, with a representative office in Jakarta. With over 3.2 billion vaccine doses produced annually, Bio Farma exports to more than 150 countries. It is the parent of two listed firms on the Indonesia Stock Exchange: PT Kimia Farma Tbk (KAEF) and PT Indofarma Tbk (INAF). More info: www.biofarma.co.id.
For press information, kindly contact:
PT Bio Farma (Persero)
Zaki Zakaria
Corporate Communication
BioNet Europe
Pierre Jean-François
+66972253710
www.bionet.one
BioNet Asia
Supachai Nampornchaisakul
+66866235157
www.bionet-asia.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/bionet-and-bio-farma-sign-strategic-mou-to-expand-tdap-vaccine-access-in-asean-302470872.html
SOURCE BioNet